Aprogen Medicines Inc.
KRX:007460.KS
1195 (KRW) • At close October 17, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) KRW.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 150,577.975 | 78,349.308 | 141,247.002 | 127,142.624 | 78,248.841 | 51,047.023 | 44,897.115 | 54,835.626 | 65,931.704 | 76,535.323 | 103,040.328 | 170,688.128 | 354,366.069 | 232,257.161 | 226,328.109 | 273,131.523 | 129,420.987 |
| Cost of Revenue
| 126,750.923 | 72,195.99 | 109,996.959 | 92,677.717 | 58,893.35 | 41,864.066 | 40,600.896 | 44,896.061 | 54,880.855 | 62,019.65 | 94,127.974 | 139,197.333 | 338,823.596 | 202,008.497 | 189,441.865 | 233,983.62 | 104,525.362 |
| Gross Profit
| 23,827.053 | 6,153.318 | 31,250.043 | 34,464.908 | 19,355.491 | 9,182.957 | 4,296.22 | 9,939.565 | 11,050.849 | 14,515.673 | 8,912.354 | 31,490.795 | 15,542.473 | 30,248.664 | 36,886.244 | 39,147.903 | 24,895.625 |
| Gross Profit Ratio
| 0.158 | 0.079 | 0.221 | 0.271 | 0.247 | 0.18 | 0.096 | 0.181 | 0.168 | 0.19 | 0.086 | 0.184 | 0.044 | 0.13 | 0.163 | 0.143 | 0.192 |
| Reseach & Development Expenses
| 44,071.512 | 38,560.516 | 1,976.787 | 1,028.612 | 1,870.896 | 4,380.686 | 407.046 | 359.751 | 0 | 0 | 0 | 0 | 543.255 | 1,074.185 | 1,880.211 | 1,838.819 | 1,367.14 |
| General & Administrative Expenses
| 20,828.579 | 29,086.515 | 3,876.162 | 3,933.94 | 2,190.506 | 153.46 | 152.472 | 152.801 | 132.371 | 317.645 | 445.048 | 1,070.29 | 3,156.778 | 2,367.162 | 2,287.107 | 2,281.266 | 1,696.522 |
| Selling & Marketing Expenses
| 20,013.373 | 11,875.482 | 11,808.462 | 8,128.584 | 4,636.373 | 467.5 | 197.204 | 169.539 | 188.939 | 334.579 | 703.62 | 1,948.897 | 12,198.82 | 5,297.615 | 4,734.925 | 4,243.53 | 3,600.303 |
| SG&A
| 74,725.719 | 40,961.997 | 15,684.623 | 12,062.524 | 6,826.879 | 620.96 | 349.676 | 322.34 | 321.31 | 652.224 | 1,148.668 | 3,019.187 | 15,355.598 | 7,664.777 | 7,022.032 | 6,524.796 | 5,296.825 |
| Other Expenses
| 2,550.914 | 40,982.878 | 16,260.946 | 17,402.591 | 8,090.73 | 207.362 | 661.199 | 407.073 | 2,996.772 | 6,431.607 | 6,598.61 | 1,428.811 | -6,930.246 | -9,223.267 | 336.953 | -372.133 | 38.446 |
| Operating Expenses
| 118,797.232 | 120,505.391 | 33,922.357 | 30,493.727 | 16,788.505 | 7,608.985 | 2,465.425 | 4,875.167 | 5,035.59 | 5,911.986 | 4,502.744 | 7,487.254 | 37,192.986 | 19,784.052 | 19,430.457 | 17,954.959 | 13,351.624 |
| Operating Income
| -94,970.179 | -114,352.074 | -2,672.314 | 5,625.355 | 41,437.34 | 1,573.972 | 1,830.795 | 5,064.397 | 6,015.26 | 8,603.687 | 4,409.611 | 24,003.541 | -21,650.512 | 10,464.612 | 17,455.789 | 21,192.945 | 11,544 |
| Operating Income Ratio
| -0.631 | -1.46 | -0.019 | 0.044 | 0.53 | 0.031 | 0.041 | 0.092 | 0.091 | 0.112 | 0.043 | 0.141 | -0.061 | 0.045 | 0.077 | 0.078 | 0.089 |
| Total Other Income Expenses Net
| -269.207 | -1,258.989 | -6,509.301 | -44,741.943 | -24,514.827 | -23,579.154 | -667.766 | -1,742.467 | -2,623.939 | 3,841.587 | -6,674.978 | -11,933.653 | -62,190.758 | -22,128.429 | -10,711.763 | -12,378.219 | -3,013.856 |
| Income Before Tax
| -95,239.386 | -115,611.062 | -9,181.615 | -39,116.588 | 16,922.513 | -22,005.182 | 1,163.029 | 3,321.931 | 3,391.32 | 12,445.273 | -2,265.368 | 12,069.889 | -83,841.271 | -11,663.817 | 6,744.024 | 8,814.725 | 8,530.145 |
| Income Before Tax Ratio
| -0.632 | -1.476 | -0.065 | -0.308 | 0.216 | -0.431 | 0.026 | 0.061 | 0.051 | 0.163 | -0.022 | 0.071 | -0.237 | -0.05 | 0.03 | 0.032 | 0.066 |
| Income Tax Expense
| 2,043.93 | 473.8 | 3,318.737 | -6,448.454 | -1,403.262 | 2,910.45 | -1,177.752 | 914.573 | 1,093.792 | 10,430.869 | 1,319.432 | 486.098 | -2,804.265 | 2,864.15 | 2,209.221 | -2.354 | 1,539.755 |
| Net Income
| -55,619.382 | -116,084.862 | -12,500.351 | -32,668.134 | 18,325.775 | -32,108.236 | 2,340.781 | 2,407.358 | 3,391.32 | 12,445.273 | -51,128.204 | -12,073.669 | -52,545.647 | -13,632.123 | 4,397.799 | 9,746.616 | 6,906.158 |
| Net Income Ratio
| -0.369 | -1.482 | -0.088 | -0.257 | 0.234 | -0.629 | 0.052 | 0.044 | 0.051 | 0.163 | -0.496 | -0.071 | -0.148 | -0.059 | 0.019 | 0.036 | 0.053 |
| EPS
| -235.5 | -1,730.97 | -194.12 | -577.78 | 402.11 | -1,895.62 | 350.93 | 440.91 | 863.83 | 3,578.28 | -17,165.57 | -7,584.13 | -39,772.66 | -10,326.88 | 3,442.29 | 8,071.58 | 7,836.96 |
| EPS Diluted
| -235.5 | -1,720.75 | -194.12 | -577.78 | 402.11 | -1,895.62 | 350.93 | 395.92 | 698.86 | 1,988.6 | -17,165.57 | -7,584.13 | -39,772.66 | -10,326.88 | 3,371.07 | 8,071.58 | 7,836.96 |
| EBITDA
| -65,940.203 | -65,173.207 | -6,399.497 | 9,933.713 | 44,688.296 | -823.913 | 4,478.904 | 7,514.174 | 9,408.728 | 21,392.064 | 13,363.087 | 44,289.897 | -21,911.59 | 6,614.214 | 22,423.198 | 24,726.081 | 16,529.232 |
| EBITDA Ratio
| -0.438 | -0.832 | -0.045 | 0.078 | 0.571 | -0.016 | 0.1 | 0.137 | 0.143 | 0.28 | 0.13 | 0.259 | -0.062 | 0.028 | 0.099 | 0.091 | 0.128 |